Johnson & Johnson's Q3 2017 earnings call highlighted strong performance, particularly in the Pharmaceutical segment driven by oncology and immunology growth.  Management discussed market share gains for key brands like Darzalex, Stelara, and Imbruvica, as well as successful new product launches.  While the Medical Devices segment experienced a modest impact from hurricanes, the overall results and management's tone suggest a positive short-term outlook for the stock.
[1]
